Go Pro
NASDAQ:PMVP

PMV Pharmaceuticals Q3 2025 Earnings Report

PMV Pharmaceuticals logo
$1.26 +0.05 (+3.70%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.26 0.00 (0.00%)
As of 08/14/2026 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.40
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
8:00AM ET

PMV Pharmaceuticals Earnings Headlines

PMV Pharmaceuticals, Inc.
The chart Wall Street hopes you never see
The Buffett Indicator, which measures total stock market value against GDP, just hit 229.9 percent, higher than 1999 and 2021 and near the highest level ever recorded. Warren Buffett once called readings near 200 percent playing with fire. His firm now holds a record 397 billion dollars in cash. Chief Investment Strategist Alexander Green says the real story isn't a crash, but a coming divide in AI stocks between overvalued names and an overlooked minority.tc pixel
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile